Monday, The U.S Food and Drug Administration had issued an emergency use authorization for Eli Lilly And Co’s monoclonal antibody therapy to help treat mild to moderate coronavirus cases in adults and children.
The bamlanivimab, a single antibody treatment, would help the patients build a strong immune response against the virus. “Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells,” the FDA said in a statement.
Dr. Patrizia Cavazzoni, acting director of the FDA’s Center for Drug Evaluation and Research, said that this tool would help the frontline health professionals in treating COVID-19 patients. Even as the antibody is available, they will still collect new data to ensure the safety and efficiency of the bamlanivimab to multiple groups of people.
Phase 2 of the trial of this antibody, it involved 452 patients, with some receiving treatment and some receiving placebo – only 1.6% of the patients that received the treatment have continued symptoms of the virus, while the latter being 6.3%.
The company announced that the government had given them a $375 million deal for 300,000 vials of the antibody treatment, with pending EUA that would most probably be delivered by December. By the end of 2020, 100,000 doses will be ready to ship within days, manufacturing a million doses that would be provided to the patients with no charge.
Lilly will ship the antibody to AmerisourceBergen, a national distributor, as directed by the U.S government’s allocation program.
The treatment should be given immediately after one has been tested positive for COVID-19, within 10 days to be precise, said FDA. The antibody, however, must be given in a hospitalized setting where professionals can monitor, in case the patient has a bad reaction towards the drug. Any effects must be reported to the FDA for data.
The treatment though is not authorized to be used on patients who are hospitalized or need oxygen therapy, as the drug is for mild and moderate coronavirus.
As soon as the COVID-19 outbreak, Lilly had started to work on the antibody to help the body naturally fight off the virus, going to clinical trials in June as soon as they found the best virus-neutralization way.
Currently, there are 79 antibody therapies under investigation, with Regeneron applying for emergency use authorization, the one given to President Trump when he caught the virus.
The hope for the drugs to be reached to people all over the globe, as they have been with trial and error, surely everyone would appreciate the sacrifices of those who didn’t make it; because without them, none of this is possible.
Source: CNN Health
